Basking Ridge, NJ-based Regado Biosciences has raised $11.6 million, according to a regulatory filing. The company’s lead compound is an anticoagulant for patients suffering from acute coronary syndrome. It is also working on a treatment for venous thrombosis and is searching for antiplatelet therapies. The most recent funding was part of a $21.5 million round. The company previously raised $23 million in 2007 and $20 million in 2005. Its investors include Caxton Advantage Life Sciences Fund, Quaker BioVentures, and Domain Associates.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
